Neuronetics (STIM) announced that it has settled the litigation filed in the District of Delaware against BrainsWay (BWAY) and BrainsWay USA Inc. for unfair competition under the Lanham Act and state law. Under the terms of the settlement, BrainsWay agreed to stop the use of the efficacy data for the treatment of anxious depression with NeuroStar Advanced Therapy for Mental Health that was at issue in the Complaint filed by Neuronetics. The parties have agreed to keep the additional terms of the settlement agreement confidential.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on STIM:
- Neuronetics Settles Litigation Against BrainsWay
- Neuronetics momentum likely to prove durable, says Piper Sandler
- Neuronetics sees Q4 revenue $18M, consensus $16.54M
- Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2022 Financial Results
- Neuronetics Announces Appointment of Joseph H. Capper to its Board of Directors